/
RSS Feed
Ozanimod, a drug for multiple sclerosis originating at Scripps Research, has been submitted for European approval by Celgene.
A U.S. Food and Drug Administration marketing application is also on track for filing by the end of March, the New Jersey-based drug company said Monday. The FDA rejected…
